Selective class IIa HDAC inhibitors: Myth or reality

Cellular and Molecular Life Sciences

Volumn 72, Issue 1, 2015, Pages 73-86

  Di Giorgio, Eros ^a   Gagliostro, Enrico ^a   Brancolini, Claudio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Anti cancer; Apoptosis; Cell cycle; HDAC3; HDAC4; HDAC5; HDAC7; HDAC9; Inflammation; MEF2; Neurodegeneration; p21; SAHA; Therapy

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ANIMAL; CHEMISTRY; DISEASES; ENZYMOLOGY; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; DISEASE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84925228971     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1727-8     Document Type: Article

References (118)

1. Gräff J, Tsai L-H (2013) Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci 14:97-111. doi: 10.1038/nrn3427
2. Helin K, Dhanak D (2013) Chromatin proteins and modifications as drug targets. Nature 502:480-488. doi: 10.1038/nature12751
3. Hatziapostolou M, Iliopoulos D (2011) Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68:1681-1702. doi: 10.1007/s00018-010-0624-z
4. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12-27. doi: 10.1016/j.cell.2012.06.013
5. Wang Z, Zang C, Cui K et al (2009) Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138:1019-1031. doi: 10.1016/j.cell.2009.06.049
6. Mihaylova MM, Vasquez DS, Ravnskjaer K et al (2011) Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145:607-621. doi: 10.1016/j.cell.2011.03.043
7. Yang X-J, Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9:206-218. doi: 10.1038/nrm2346
8. Delcuve G, Khan D, Davie J (2012) Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenenetics 4:5. doi: 10.1186/1868-7083-4-5
9. Di Micco R, Sulli G, Dobreva M et al (2011) Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol 13:292-302. doi: 10.1038/ncb2170
10. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. doi: 10.1038/nrd2133
11. Henderson C, Brancolini C (2003) Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. Drug Resist Updat 6:247-256. doi: 10.1016/S1368-7646(03)00067-0
12. Clocchiatti A, Florean C, Brancolini C (2011) Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. J Cell Mol Med 15:1833-1846. doi: 10.1111/j.1582-4934.2011.01321.x
13. Aygün O, Mehta S, Grewal SIS (2013) HDAC-mediated suppression of histone turnover promotes epigenetic stability of heterochromatin. Nat Struct Mol Biol 20:547-554. doi: 10.1038/nsmb.2565
14. Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969. doi: 10.1158/1078-0432.CCR-08-2785
15. Balasubramanian S, Verner E, Buggy JJ (2009) Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 280:211-221. doi: 10.1016/j.canlet.2009.02.013
16. Bertrand P (2010) Inside HDAC with HDAC inhibitors. Eur J Med Chem 45:2095-2116. doi: 10.1016/j.ejmech.2010.02.030
17. Giannini G, Cabri W, Fattorusso C, Rodriquez M (2012) Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 4:1439-1460. doi: 10.4155/fmc.12.80
18. Thaler F, Mercurio C (2014) Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. Chem Med Chem 9:523-536. doi: 10.1002/cmdc.201300413
19. Dekker FJ, van den Bosch T, Martin NI (2014) Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. Drug Discov Today 19:654-660. doi: 10.1016/j.drudis.2013.11.012
20. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981-989. doi: 10.1158/1541-7786.MCR-07-0324
21. West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124:30-39. doi: 10.1172/JCI69738
22. Zhang J, Zhong Q (2014) Histone deacetylase inhibitors and cell death. Cell Mol Life Sci. doi: 10.1007/s00018-014-1656-6
23. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32-42. doi: 10.1038/nrg2485
24. Fischle W, Dequiedt F, Hendzel MJ et al (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9:45-57. doi: 10.1016/S1097-2765(01)00429-4
25. Lahm A, Paolini C, Pallaoro M et al (2007) Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 104:17335-17340. doi: 10.1073/pnas.0706487104
26. Lobera M, Madauss KP, Pohlhaus DT et al (2013) Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 9:319-325. doi: 10.1038/nchembio.1223
27. Martin M, Kettmann R, Dequiedt F (2007) Class IIa histone deacetylases: regulating the regulators. Oncogene 26:5450-5467. doi: 10.1038/sj.onc.1210613
28. Wang Z, Qin G, Zhao TC (2014) HDAC4: mechanism of regulation and biological functions. Epigenomics 6:139-150. doi: 10.2217/epi.13.73
29. Schuetz A, Min J, Allali-Hassani A et al (2008) Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 283:11355-11363. doi: 10.1074/jbc.M707362200
30. Vannini A, Volpari C, Filocamo G et al (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101:15064-15069. doi: 10.1073/pnas.0404603101
31. Bottomley MJ, Lo Surdo P, Di Giovine P et al (2008) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 283:26694-26704. doi: 10.1074/jbc.M803514200
32. Zhou X, Marks PA, Rifkind RA, Richon VM (2001) Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA 98:10572-10577. doi: 10.1073/pnas.191375098
33. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17-31. doi: 10.1016/j.jmb.2004.02.006
34. Huang EY, Zhang J, Miska EA et al (2000) Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev 14:45-54. doi: 10.1101/gad.14.1.45
35. Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21:6091-6101. doi: 10.1128/MCB.21.18.6091-6101.2001
36. Fischle W, Dequiedt F, Fillion M et al (2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276:35826-35835. doi: 10.1074/jbc.M104935200
37. + breast tumors. FASEB J 27:942-954. doi: 10.1096/fj.12-209346
38. Di Giorgio E, Clocchiatti A, Piccinin S et al (2013) MEF2 is a converging hub for HDAC4 and PI3K/Akt-induced transformation. Mol Cell Biol 33:4473-4491. doi: 10.1128/MCB.01050-13
39. Zhang C, McKinsey T, Olson E (2002) Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 22:7302-7312. doi: 10.1128/MCB.22.20.7302
40. Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193. doi: 10.1038/43710
41. Yang W-M, Tsai S-C, Wen Y-D et al (2002) Functional domains of histone deacetylase-3. J Biol Chem 277:9447-9454. doi: 10.1074/jbc.M105993200
42. Ago T, Liu T, Zhai P et al (2008) A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133:978-993. doi: 10.1016/j.cell.2008.04.041
43. Isaacs JT, Antony L, Dalrymple SL et al (2013) Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res 73:1386-1399. doi: 10.1158/0008-5472.CAN-12-2730
44. Clocchiatti A, Di Giorgio E, Demarchi F, Brancolini C (2013) Beside the MEF2 axis: unconventional functions of HDAC4. Cell Signal 25:269-276. doi: 10.1016/j.cellsig.2012.10.002
45. Cohen TJ, Barrientos T, Hartman ZC et al (2009) The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity. FASEB J 23:99-106. doi: 10.1096/fj.08-115931
46. Moresi V, Williams AH, Meadows E et al (2010) Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 143:35-45. doi: 10.1016/j.cell.2010.09.004
47. Choi MC, Cohen TJ, Barrientos T et al (2012) A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program. Mol Cell 47:122-132. doi: 10.1016/j.molcel.2012.04.025
48. Liu L, Cavanaugh JE, Wang Y et al (2003) ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci USA 100:8532-8537. doi: 10.1073/pnas.1332804100
49. Grégoire S, Tremblay AM, Xiao L et al (2006) Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J Biol Chem 281:4423-4433. doi: 10.1074/jbc.M509471200
50. Grégoire S, Xiao L, Nie J et al (2007) Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 27:1280-1295. doi: 10.1128/MCB.00882-06
51. Burgess A, Ruefli A, Beamish H et al (2004) Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23:6693-6701. doi: 10.1038/sj.onc.1207893
52. Bolden JE, Shi W, Jankowski K et al (2013) HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 4:e519. doi: 10.1038/cddis.2013.9
53. Vrana JA, Decker RH, Johnson CR et al (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18:7016-7025. doi: 10.1038/sj.onc.1203176
54. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019. doi: 10.1073/pnas.180316197
55. Gammoh N, Lam D, Puente C et al (2012) Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci 109:6561-6565. doi: 10.1073/pnas.1204429109
56. Henderson C, Mizzau M, Paroni G et al (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579-12589. doi: 10.1074/jbc.M213093200
57. Maeda T, Towatari M, Kosugi H, Saito H (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96:3847-3856
58. Magner WJ, Kazim AL, Stewart C et al (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017-7024
59. Rossig L, Li H, Fisslthaler B et al (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91:837-844. doi: 10.1161/01.RES.0000037983.07158.B1
60. Deroanne CF, Bonjean K, Servotte S et al (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427-436. doi: 10.1038/sj.onc.1205108
61. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468. doi: 10.1200/JCO.2009.22.1291
62. Wilson AJ, Byun D-S, Nasser S et al (2008) HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19:4062-4075. doi: 10.1091/mbc.E08-02-0139
63. Mottet D, Pirotte S, Lamour V et al (2009) HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28:243-256. doi: 10.1038/onc.2008.371
64. Rad R, Rad L, Wang W et al (2010) PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 330:1104-1107. doi: 10.1126/science.1193004
65. Hohl M, Wagner M, Reil J et al (2013) HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest 123:1359-1370. doi: 10.1172/JCI61084
66. Jones P, Altamura S, De Francesco R et al (2008) Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 18:1814-1819. doi: 10.1016/j.bmcl.2008.02.025
67. Jones P, Bottomley MJ, Carfí A et al (2008) 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett 18:3456-3461. doi: 10.1016/j.bmcl.2008.02.026
68. Bradner JE, West N, Grachan ML et al (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243. doi: 10.1038/nchembio.313
69. Sternson SM, Wong JC, Grozinger CM, Schreiber SL (2001) Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 3:4239-4242. doi: 10.1021/ol016915f
70. Henkes LM, Haus P, Jäger F et al (2012) Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases. Bioorg Med Chem 20:985-995. doi: 10.1016/j.bmc.2011.11.041
71. Marek L, Hamacher A, Hansen FK et al (2013) Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem 56:427-436. doi: 10.1021/jm301254q
72. Fleming CL, Ashton TD, Gaur V et al (2014) Improved synthesis and structural reassignment of MC1568: a class IIa selective HDAC inhibitor. J Med Chem 57:1132-1135. doi: 10.1021/jm401945k
73. Mai A, Massa S, Pezzi R et al (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48:3344-3353. doi: 10.1021/jm049002a
74. Duong V, Bret C, Altucci L et al (2008) Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 6:1908-1919. doi: 10.1158/1541-7786.MCR-08-0299
75. Nebbioso A, Dell'Aversana C, Bugge A et al (2010) HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol 45:219-228. doi: 10.1677/JME-10-0043
76. Venza I, Visalli M, Oteri R et al (2013) Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res 26:193-204. doi: 10.1111/pcmr.12049
77. Kahali B, Gramling SJ, Marquez SB et al (2014) Identifying targets for the restoration and reactivation of BRM. Oncogene 33:653-664. doi: 10.1038/onc.2012.613
78. Nebbioso A, Manzo F, Miceli M et al (2009) Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 10:776-782. doi: 10.1038/embor.2009.88
79. Ontoria JM, Altamura S, Di Marco A, Ferrigno F, Laufer R, Muraglia E, Palumbi MC, Rowley M, Scarpelli R, Schultz-Fademrecht C, Serafini S, Steinkühler CJP (2009) Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem 52:6782-6789. doi: 10.1021/jm900555u
80. Tessier P, Smil DV, Wahhab A et al (2009) Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett 19:5684-5688. doi: 10.1016/j.bmcl.2009.08.010
81. Haus P, Korbus M, Schröder M, Meyer-Almes F-J (2011) Identification of selective class II histone deacetylase inhibitors using a novel dual-parameter binding assay based on fluorescence anisotropy and lifetime. J Biomol Screen 16:1206-1216. doi: 10.1177/1087057111424605
82. Olsson A, Björk A, Vallon-Christersson J et al (2010) Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 9:107. doi: 10.1186/1476-4598-9-107
83. Dalrymple SL, Becker RE, Zhou H et al (2012) Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 72:638-648. doi: 10.1002/pros.21467
84. Corzo CA, Condamine T, Lu L et al (2010) HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207:2439-2453. doi: 10.1084/jem.20100587
85. Kong Y, Jung M, Wang K et al (2011) Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther 10:1591-1599. doi: 10.1158/1535-7163.MCT-10-0779
86. Zhang Y, Li N, Caron C et al (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22:1168-1179. doi: 10.1093/emboj/cdg115
87. Geng L, Cuneo KC, Fu A et al (2006) Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66:11298-11304. doi: 10.1158/0008-5472.CAN-06-0049
88. Guo L, Han A, Bates DL et al (2007) Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains. Proc Natl Acad Sci USA 104:4297-4302. doi: 10.1073/pnas.0608041104
89. Miska EA, Karlsson C, Langley E et al (1999) HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 18:5099-5107. doi: 10.1093/emboj/18.18.5099
90. Vega RB, Matsuda K, Oh J et al (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555-566. doi: 10.1016/j.cell.2004.10.024
91. Chang S, McKinsey TA, Zhang CL et al (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467-8476. doi: 10.1128/MCB.24.19.8467-8476.2004
92. Chang S, Young BD, Li S et al (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126:321-334. doi: 10.1016/j.cell.2006.05.040
93. Kehat I, Accornero F, Aronow BJ, Molkentin JD (2011) Modulation of chromatin position and gene expression by HDAC4 interaction with nucleoporins. J Cell Biol 193:21-29. doi: 10.1083/jcb.201101046
94. Barrett A, Santangelo S, Tan K et al (2007) Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer 121:265-275. doi: 10.1002/ijc.22673
95. Jayathilaka N, Han A, Gaffney KJ et al (2012) Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res 40:5378-5388. doi: 10.1093/nar/gks189
96. Han A, He J, Wu Y et al (2005) Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J Mol Biol 345:91-102. doi: 10.1016/j.jmb.2004.10.033
97. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51. doi: 10.1038/nrc1779
98. Shi Y, Lan F, Matson C et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941-953. doi: 10.1016/j.cell.2004.12.012
99. Metzger E, Wissmann M, Yin N et al (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436-439. doi: 10.1038/nature04020
100. Hoffmann I, Roatsch M, Schmitt ML et al (2012) The role of histone demethylases in cancer therapy. Mol Oncol 6:683-703. doi: 10.1016/j.molonc.2012.07.004
101. Zhuang Q, Qing X, Ying Y et al (2013) Class IIa histone deacetylases and myocyte enhancer factor 2 proteins regulate the mesenchymal-to-epithelial transition of somatic cell reprogramming. J Biol Chem 288:12022-12031. doi: 10.1074/jbc.M113.460766
102. McGee SL, van Denderen BJW, Howlett KF et al (2008) AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 57:860-867. doi: 10.2337/db07-0843
103. Sparling DP, Griesel BA, Weems J, Olson AL (2008) GLUT4 enhancer factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT4 promoter in adipocytes. J Biol Chem 283:7429-7437. doi: 10.1074/jbc.M800481200
104. Weems J, Olson AL (2011) Class II histone deacetylases limit GLUT4 gene expression during adipocyte differentiation. J Biol Chem 286:460-468. doi: 10.1074/jbc.M110.157107
105. Raichur S, Hooi Teh S, Ohwaki K et al (2012) Histone deacetylase 5 regulates glucose uptake and insulin action in muscle cells. J Mol Endocrinol 49:203-211. doi: 10.1530/JME-12-0095
106. Kumar A, Lin Z, SenBanerjee S, Jain MK (2005) Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases. Mol Cell Biol 25:5893-5903. doi: 10.1128/MCB.25.14.5893-5903.2005
107. Baek Y-S, Haas S, Hackstein H et al (2009) Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells. BMC Immunol 10:18. doi: 10.1186/1471-2172-10-18
108. Bolger TA, Zhao X, Cohen TJ et al (2007) The neurodegenerative disease protein ataxin-1 antagonizes the neuronal survival function of myocyte enhancer factor-2. J Biol Chem 282:29186-29192. doi: 10.1074/jbc.M704182200
109. Morrison BE, Majdzadeh N, D'Mello SR (2007) Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64:2258-2269. doi: 10.1007/s00018-007-7035-9
110. West AE (2012) Regulated shuttling of the histone deacetylase HDAC5 to the nucleus may put a brake on cocaine addiction. Neuron 73:1-3. doi: 10.1016/j.neuron.2011.12.016
111. Li J, Chen J, Ricupero CL et al (2012) Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med 18:783-790. doi: 10.1038/nm.2709
112. Hara N, Alkanani AK, Dinarello CA, Zipris D (2014) Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. J Mol Med 92:93-102. doi: 10.1007/s00109-013-1078-1
113. Herman D, Jenssen K, Burnett R et al (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2:551-558. doi: 10.1038/nchembio815
114. Burli RW, Luckhurst CA, Aziz O et al (2013) Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. J Med Chem 56:9934-9954. doi: 10.1021/jm4011884
115. Tao R, de Zoeten EF, Ozkaynak E et al (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13:1299-1307. doi: 10.1038/nm1652
116. Wang L, de Zoeten EF, Greene MI, Hancock WW (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 8:969-981. doi: 10.1038/nrd3031
117. de Zoeten EF, Wang L, Sai H et al (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138:583-594. doi: 10.1053/j.gastro.2009.10.037
118. Bantscheff M, Hopf C, Savitski MM et al (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29:255-265. doi: 10.1038/nbt.175